Skip to content

XOMA Corporation XOMA Gain (loss) on mark-to-market of Escrowed Shares

Gain (loss) on mark-to-market of Escrowed Shares at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
-$837K-381%

Segments

By segment

See full
Single Reportable$12K

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$746.04M+159%
Enterprise value$785.17M+152%
P/E22.1×
P/S15.4×+8.7×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Reported directly by XOMA Corporation in its filing.

Tagged under the XBRL concept us-gaap:UnrealizedGainLossOnDerivatives.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's gain (loss) on mark-to-market of escrowed shares.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's gain (loss) on mark-to-market of escrowed shares?
XOMA Corporation (XOMA) reported gain (loss) on mark-to-market of escrowed shares of $12K in Q1 2026.
What does gain (loss) on mark-to-market of escrowed shares mean?
Captures the non-cash change in the fair value of derivative instruments, such as mark-to-market adjustments on escrowed shares or hedging contracts. This metric isolates volatility driven by market price movements from the company's core royalty business operations. It helps investors understand the impact of financial market fluctuations on the company's reported earnings.